JP2021522295A5 - - Google Patents
Info
- Publication number
- JP2021522295A5 JP2021522295A5 JP2020561004A JP2020561004A JP2021522295A5 JP 2021522295 A5 JP2021522295 A5 JP 2021522295A5 JP 2020561004 A JP2020561004 A JP 2020561004A JP 2020561004 A JP2020561004 A JP 2020561004A JP 2021522295 A5 JP2021522295 A5 JP 2021522295A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- prion
- pharmaceutical composition
- composition according
- serpina3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18170092.3 | 2018-04-30 | ||
| EP18170092.3A EP3563848A1 (en) | 2018-04-30 | 2018-04-30 | Serpin inhibitors for the treatment of prion and prion-like diseases |
| PCT/EP2019/061014 WO2019211265A1 (en) | 2018-04-30 | 2019-04-30 | Serpin inhibitors for the treatment of prion and prion-like diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021522295A JP2021522295A (ja) | 2021-08-30 |
| JP2021522295A5 true JP2021522295A5 (enExample) | 2022-05-12 |
Family
ID=62104124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561004A Withdrawn JP2021522295A (ja) | 2018-04-30 | 2019-04-30 | プリオンおよびプリオン様疾患の治療のためのｓｅｒｐｉｎ阻害剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20210093626A1 (enExample) |
| EP (2) | EP3563848A1 (enExample) |
| JP (1) | JP2021522295A (enExample) |
| WO (1) | WO2019211265A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120392971A (zh) * | 2025-04-30 | 2025-08-01 | 北京蓬勃力量生物科技有限公司 | 一种重组蛋白在治疗肌肉萎缩中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ284157B6 (cs) * | 1992-12-17 | 1998-08-12 | Pfizer Inc. | Pyrazolové a pyrazolopyrimidinové sloučeniny jako takové a pro léčbu chorob a farmaceutické prostředky na jejich bázi |
| US6316466B1 (en) * | 1998-05-05 | 2001-11-13 | Syntex (U.S.A.) Llc | Pyrazole derivatives P-38 MAP kinase inhibitors |
| HRP20000724A2 (en) * | 1998-05-05 | 2001-06-30 | Hoffmann La Roche | Pyrazole derivatives as p-38 map kinase inhibitors |
| PL2298743T3 (pl) * | 2003-06-26 | 2013-02-28 | Novartis Ag | Inhibitory kinaz P38 na bazie 5-członowych heterocykli |
| EP2099766A1 (en) * | 2006-12-20 | 2009-09-16 | Glaxo Group Limited | Pyrazole derivatives as non-steroidal glucocorticoid receptor ligands |
| EP2415471A1 (en) * | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
-
2018
- 2018-04-30 EP EP18170092.3A patent/EP3563848A1/en not_active Withdrawn
-
2019
- 2019-04-30 US US17/051,385 patent/US20210093626A1/en not_active Abandoned
- 2019-04-30 JP JP2020561004A patent/JP2021522295A/ja not_active Withdrawn
- 2019-04-30 EP EP19722552.7A patent/EP3787619B1/en active Active
- 2019-04-30 WO PCT/EP2019/061014 patent/WO2019211265A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huang et al. | Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update | |
| JP6517827B2 (ja) | イソインドリン組成物および神経変性疾患の治療方法 | |
| JP2019510006A5 (enExample) | ||
| JP2008520589A5 (enExample) | ||
| NZ788543A (en) | Dimethyltryptamine derivatives and their use in psychedelic-assisted psychotherapy | |
| CN106470991B (zh) | 在中枢神经系统障碍治疗中的2,4-噻唑烷二酮衍生物 | |
| JP2019533642A5 (enExample) | ||
| JP2019506430A5 (enExample) | ||
| JP2018534286A5 (enExample) | ||
| BRPI0607860A2 (pt) | composição farmacêutica para o tratamento ou prevenção de doenças envolvendo obesidade, diabetes, sìndrome metabólica, doenças neuro--degenerativas e doenças de disfunção da mitocÈndria | |
| WO2021255737A1 (en) | Hydroxynorketamine analogues, compositions comprising same and methods of use thereof | |
| JP2019530674A5 (enExample) | ||
| MX2023013683A (es) | Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a). | |
| CN114641287A (zh) | 神经退行性病症的治疗和预防 | |
| JP2021522295A5 (enExample) | ||
| JP2016537432A5 (enExample) | ||
| JP2019501167A5 (enExample) | ||
| US20230263806A1 (en) | Methods of treating proteinopathies | |
| JP2022523668A5 (enExample) | ||
| WO2010005581A4 (en) | Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of alzheimer's disease (ad) | |
| JP2022510587A5 (enExample) | ||
| JP2019501875A5 (enExample) | ||
| CA3148794A1 (en) | 4-amino-quinolines/-quinazolines that bind to tdp-43 for the treatment of amyotrophic lateral sclerosis and related disorders | |
| RU2013131161A (ru) | Производное 2-карбоксамид-4-пиперазинил-бензофурана | |
| BR112022011810A2 (pt) | Compostos inibidores de oga |